from the domestic market and therefore do not have significant foreign exchange fluctuation risks. The Company does not use any derivative contracts to hedge exposure to fluctuations in commodity prices.

k. Policy on Protection of Women against Sexual Harassment at Workplace

In order to ensure a safe and harassment-free workplace for its female employees, the Company has implemented a Policy on the Protection of Women against Sexual Harassment at Workplace. This encourages female employees to pursue their careers without any fear of prejudice, gender bias, sexual harassment and / or any other such implicit or explicit orientation. In accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, Complaint Redressal Committees are formed at administrative units / offices for this purpose.

During the year 2021-22, there were no complaints registered under SHP forum.

I. Mandatory & Non-Mandatory Clauses

The Company has complied with all mandatory requirements laid down by Listing Regulations including those specified in Regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46.

The non-mandatory requirements complied with are disclosed below:

Audit Qualification: The Company's financial statements for the year 2021-22 do not contain any modified audit opinion. Reporting of Internal Auditors: The Internal Auditors present their internal audit observations quarterly to the Audit Committee.

9. COMMUNICATION TO SHAREHOLDERS

During the year, audited quarterly and annual financial results on standalone basis and un-audited quarterly and audited annual financial results on a consolidated basis of the Company were submitted to the stock exchanges soon after the Board meeting approved these and were published in leading newspapers viz The Financial Express and The Indian Express in all edition of English language and The Financial Express in Gujarati language. These were also promptly put on the Company's website <u>www.torrentpharma.com</u>. All official news release of relevance, quarterly / annual results and presentations made by the Company to investors / analysts were also made available on the Company's website. The Company sends soft copies of Annual Report to those shareholders whose e-mail ids are registered with the Depository Participants and / or with the Company's Registrars and Transfer Agents, unless opted by them to get the physical copy, to support the "Green Initiative in Corporate Governance" of the Ministry of Corporate Affairs.

10. GENERAL SHAREHOLDER INFORMATION

a. 49th AGM

| Date & Time | Friday, 29th July, 2022 at 09:30 AM |
|-------------|---|
| Venue | The Company is going to conduct the meeting through VC / OAVM pursuant to the MCA circular |
| | dated 5 th May, 2020 read with MCA circular dated 5 th May, 2022 and as such there is no requirement to have a venue for the AGM. For details please refer to the Notice of this AGM. |

b. Tentative Financial Calendar for the year 2022-23

| Financial year | 1 st April to 31 st March |
|-----------------------|---|
| First Quarter results | Fourth week of July 2022 |
| Half Yearly results | Third week of October 2022 |
| Third Quarter results | Fourth week of January 2023 |
| Results for year-end | Second week of May 2023 |

c. Record date

6th June, 2022

d. Dividend payment date

The proposed dividend, if approved at the ensuing AGM will be distributed around 4th August, 2022.

e. Listing on Stock Exchanges and Security Codes

| Name of Stock Exchange | Security Code |
|--|---------------|
| A. Equity shares | |
| BSE Limited, Mumbai (BSE) | 500420 |
| National Stock Exchange of India Limited, Mumbai (NSE) | TORNTPHARM |
| B. Non-Convertible Debentures | |
| National Stock Exchange of India Limited, Mumbai (NSE) | |

The Company has paid the annual listing fees for the year 2022-23 to both the above stock exchanges.

f. Market Price Data

The closing market price of equity share on 31st March, 2022 (last trading day of the year) was ₹ 2,796.30 on BSE & ₹ 2,791.95 on NSE.


The monthly movement of equity share prices during the year at BSE & NSE are summarized below:

Monthly Share Price movement during the financial year ended 31st March, 2022 at BSE & NSE:

| | | | | | | (share price in ₹) |
|--|----------|----------|-----------|----------|----------|--------------------|
| Month | BSE | | | NSE | | |
| | High | Low | Volume | High | Low | Volume |
| Apr-21 | 2,680.00 | 2,477.65 | 2,37,171 | 2,682.00 | 2,475.50 | 55,53,674 |
| May-21 | 2,891.55 | 2,486.60 | 3,60,364 | 2,892.00 | 2,484.95 | 81,14,169 |
| Jun-21 | 3,007.00 | 2,715.00 | 2,25,613 | 3,009.50 | 2,715.00 | 52,68,655 |
| Jul-21 | 3,121.45 | 2,882.95 | 2,91,089 | 3,144.00 | 2,883.00 | 49,39,842 |
| Aug-21 | 3,156.45 | 2,855.85 | 1,71,877 | 3,157.90 | 2,854.00 | 38,28,318 |
| Sep-21 | 3,248.00 | 3,017.60 | 5,04,298 | 3,250.20 | 3,019.25 | 25,05,215 |
| Oct-21 | 3,200.00 | 2,765.65 | 2,01,827 | 3,203.00 | 2,766.00 | 27,07,311 |
| Nov-21 | 3,248.00 | 2,734.50 | 3,71,258 | 3,248.80 | 2,735.30 | 69,90,964 |
| Dec-21 | 3,304.45 | 2,919.20 | 1,67,279 | 3,298.50 | 2,924.75 | 53,41,854 |
| Jan-22 | 3,299.90 | 2,601.30 | 1,93,055 | 3,295.95 | 2,615.00 | 58,31,997 |
| Feb-22 | 2,775.00 | 2,540.00 | 1,08,034 | 2,778.95 | 2,530.05 | 39,16,553 |
| Mar-22 | 2,985.65 | 2,651.90 | 62,758 | 2,987.75 | 2,651.00 | 36,94,521 |
| Total | | | 28,94,623 | | | 5,86,93,073 |
| % of volume traded to outstanding shares | | | 1.71% | | | 34.68% |

The performance of the equity share price of the Company vis-à-vis the S&P CNX Nifty at NSE is as under:

| Month | TPL Share Price at | S&P CNX Nifty** | Relative Index for comparison purpose | | |
|-----------------|---------------------------|-----------------|---------------------------------------|---------------|--|
| | NSE** | | TPL share price index | S&P CNX Nifty | |
| Mar-21 | 2,545.05 | 14,690.70 | 100.00 | 100.00 | |
| Apr-21 | 2,509.25 | 14,631.10 | 98.59 | 99.59 | |
| May-21 | 2,741.35 | 15,582.80 | 107.71 | 106.07 | |
| Jun-21 | 2,901.60 | 15,721.50 | 114.01 | 107.02 | |
| Jul-21 | 3,071.10 | 15,763.05 | 120.67 | 107.30 | |
| Aug-21 | 3,105.90 | 17,132.20 | 122.04 | 116.62 | |
| Sep-21 | 3,085.50 | 17,618.15 | 121.24 | 119.93 | |
| Oct-21 | 2,860.40 | 17,671.65 | 112.39 | 120.29 | |
| Nov-21 | 3,042.05 | 16,983.20 | 119.53 | 115.61 | |
| Dec-21 | 3,278.45 | 17,354.05 | 128.82 | 118.13 | |
| Jan-22 | 2,671.45 | 17,339.85 | 104.97 | 118.03 | |
| Feb-22 | 2,749.90 | 16,793.90 | 108.05 | 114.32 | |
| Mar-22 | 2,791.95 | 17,464.75 | 109.70 | 118.88 | |
| ** data as on o | closing of the month | | · · · · · · · · · · · · · · · · · · · | | |



Relative Performance of TPL share price vs. S&P CNX Nifty

g. Distribution of shareholding as at 31st March, 2022

By size of shareholding:

| Category (Shares) | Mode of Holding | No. of Shares | % To Equity | No. of Holders | % To Holders |
|-------------------|--------------------|---------------|-------------|----------------|--------------|
| 1 - 1,000 | Electronic | 5,469,375 | 3.23 | 62,796 | 96.71 |
| | Physical | 305,066 | 0.18 | 680 | 1.05 |
| 1,001 - 2,000 | Electronic | 928,013 | 0.55 | 631 | 0.97 |
| | Physical | 35,200 | 0.02 | 22 | 0.03 |
| 2,001 - 10,000 | Electronic | 2,089,148 | 1.23 | 480 | 0.74 |
| | Physical | 35,200 | 0.02 | 8 | 0.01 |
| 10,001 - 20,000 | Electronic | 1,224,250 | 0.72 | 88 | 0.14 |
| | Physical | | | | |
| Above 20,000 | Electronic | 159,136,468 | 94.04 | 227 | 0.35 |
| | Physical | | | | |
| Total | Electronic | 168,847,254 | 99.78 | 64,222 | 98.91 |
| | Physical | 375,466 | 0.22 | 710 | 1.09 |
| | Total: | 169,222,720 | 100.00 | 64,932 | 100.00 |

By category of shareholders:

| Category | No. of S | ihares | Total Shares | % of Holding |
|---|-------------|----------|--------------|--------------|
| | Electronic | Physical | | |
| Promoter's Group | 120,564,720 | | 120,564,720 | 71.25 |
| Mutual Fund | 12,658,432 | | 12,658,432 | 7.48 |
| Bank, Fls, AIFs & Insurance Companies | 134,016 | | 134,016 | 0.08 |
| Foreign Institutional Investors / QIB / QFIs / NRIs | 22,396,269 | | 22,396,269 | 13.23 |
| Other Bodies Corporate | 795,534 | 3,400 | 798,934 | 0.47 |
| Indian Public | 12,116,857 | 372,066 | 12,488,923 | 7.38 |
| IEPF | 181,426 | | 181,426 | 0.11 |
| Total | 168,847,254 | 375,466 | 169,222,720 | 100.00 |

h. Dematerialisation of securities

The equity shares of the Company are traded compulsorily in the dematerialised segment of all the stock exchanges and are under rolling settlement. Approximately 99.78% of the shares have been dematerialised. Shares held by promoters are all in dematerialised form. The demat security (ISIN) code for the equity share is INE685A01028.

i. Share transfer system

SEBI vide its circular dated 25th January 2022, has mandated that listed companies shall issue the securities in dematerialized form only, in order to enhance ease of dealing in securities markets by investors, for transactions including Issue of duplicate securities certificate, claim from unclaimed suspense account, renewal / exchange of securities certificate, endorsement, sub-division / splitting of securities certificate, consolidation of securities certificates / folios, transmission and transposition of shares. Accordingly, Shareholders are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the Company's website under the link at https://www.torrentpharma.com/index.php/investors/shareHolder. The details of transmission approved by the delegates are noted by the Securities Transfer and Stakeholders Relationship Committee. The Company obtains from a Company Secretary in Practice an annual certificate of compliance with the share transfer formalities as required under Regulation 40(9) of the Listing Regulations and files a copy of the certificate with the Stock Exchanges. The Company has signed necessary agreements with two depositories currently functional in India viz. National Securities Depository Limited & Central Depository Services (India) Limited. The transfer of shares in electronic mode need not be approved by the Company.

The Company has sent individual letters to all the Members holding shares of the Company in physical form for furnishing their PAN, KYC details and Nomination pursuant to the SEBI Circular dated 3rd November, 2021. Attention of the Members holding shares of the Company in physical form is invited to go through the said important communication under the web link at <u>https://www.torrentpharma.com/index.php/investors/shareHolder.</u>

j. Credit Ratings

Details of all credit ratings obtained by the Company for its borrowings including debt instruments are as follows:

ICRA Ltd has assigned credit rating of -

- [ICRA] AA (Positive) for banking facilities and non-convertible debentures.
- [ICRA] A1+ for commercial paper program of the Company.

During the year under review, ICRA has revised rating outlook to "Positive"

India Ratings and Research Private Limited ("India Ratings") has assigned rating of -

• IND AA (Positive) for Non-convertible debentures and term loans.

During the year under review, India Ratings has revised rating outlook to "Positive"

k. Outstanding GDRs / ADRs / Warrants / any other convertible instruments

The Company does not have any outstanding instruments of the captioned type.

I. Registered Office

Torrent House, Off Ashram Road, Ahmedabad – 380 009, Gujarat, India Phone: + 91 79 26599000 Fax: + 91 79 26582100

m. Plant Locations

- 1. Village Indrad, Taluka Kadi, Dist. Mehsana (Gujarat)
- 2. Village Bhud, Baddi, Teh. Nalagarh, Dist. Solan (Himachal Pradesh)
- 3. 32 No. Middle Camp, NH-10, East District, Gangtok (Sikkim) Unit I & Unit II
- 4. NH-10, Bagheykhola Village, Majhitar, Rangpo, East Sikkim (Sikkim) Unit III
- 5. Plot No 810, Sector III, Industrial area, Pithampur, Dist Dhar (Madhya Pradesh)
- 6. Plot No.77, J N Pharma City, Thanam Village, Parawada-Mandal, Vizag (Andhra Pradesh)
- 7. Plot No. Z104-106, Dahej SEZ Phase II, Taluka Vagra, Dist. Bharuch (Gujarat).
- 8. Torrent Pharma Inc. 2091 Hartel Street, Pennsylvania 19057, U.S.A (Operations discontinued from 25th May, 2022)

n. Project Site

Bileshwarpura, Taluka Kalol, District Gandhinagar (Gujarat)

o. Research & Development Facility

Village Bhat, Dist. Gandhinagar - 382 428 (Gujarat)

p. Compliance Officer

Mahesh Agrawal VP (Legal) & Company Secretary Torrent House, Off Ashram Road, Ahmedabad – 380 009, Gujarat, India Phone: + 91 79 26599000 Fax: + 91 79 26582100 E-mail ID: maheshagrawal@torrentpharma.com

q. Investor Services

E-mail ID: investorservices@torrentpharma.com

r. Registrars & Transfer Agents (RTA)

KFIN Technologies Limited Unit: Torrent Pharmaceuticals Limited Selenium Tower-B, Plot No. 31 & 32, Financial District, Gachibowli, Hyderabad - 500 032, India Tel No: +91 40 67162222 Fax No: +91 40 23001153 Contact person: Mr. Ganesh Chandra Patro E-mail ID: <u>einward.ris@kfintech.com</u>

s. Debenture Trustee

IDBI TRUSTEESHIP SERVICES LIMITED Asian Building, Ground Floor, 17, R. Kamani Marg, Ballard Estate, Mumbai – 400 001. Website: http://www.idbitrustee.com E-mail ID: itsl@idbitrustee.com Tel. No: + 91 22 4080 7000 Fax No: +91 22 6631 1776

Ahmedabad 25th May, 2022 For and on behalf of the Board of Directors Samir Mehta Executive Chairman DIN: 00061903

ANNEXURE 1 TO CORPORATE GOVERNANCE REPORT

To The Shareholders,

Affirmation of Compliance with Code of Business Conduct

I, Samir Mehta, Executive Chairman, declare that the Board of Directors of the Company has received affirmation on compliance with the Code of Business Conduct for the period from 1st April, 2021 or the date of their joining the Company, whichever is later, to 31st March, 2022 from all Members of the Board and employees under Senior Management Cadre comprising CEO / Executive Directors (not a Member of the Board), Vice Presidents and General Managers.

Ahmedabad 25th May, 2022 Samir Mehta Executive Chairman DIN: 00061903